Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Brent McHenry

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
European Urology|October 30, 2020
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate CancerM Brent McHenry, Charles G Drake, Karim Fizazi
The New England Journal of Medicine|July 5, 2018
Immune Checkpoint Blockade in Advanced Renal-Cell CarcinomaRobert J Motzer, M Brent McHenry, Allen C Chen
Biometrika|October 11, 2012
Empirical Bayes estimation for additive hazards regression modelsDebajyoti Sinha, M Brent McHenry, Stuart R Lipsitz, et al.
American Journal of Physiology. Renal Physiology|June 29, 2007
Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathyYan Tan, Joo-Seob Keum, Bing Wang, et al.
European Urology|November 17, 2019
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214Bernard Escudier, Robert J Motzer, Nizar M Tannir, et al.
Breast Cancer Research and Treatment|May 8, 2013
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancerHope S Rugo, Mario Campone, Dino Amadori, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2008
Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetesAyad A Jaffa, William R Usinger, M Brent McHenry, et al.
Metabolism: Clinical and Experimental|September 18, 2004
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclassesRichard L Klein, M Brent McHenry, Kerry H Lok, et al.
Japanese Journal of Clinical Oncology|April 19, 2017
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 studyYoshihiko Tomita, Satoshi Fukasawa, Nobuo Shinohara, et al.
Journal of Diabetes and Its Complications|January 12, 2005
Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohortRichard L Klein, M Brent McHenry, Kerry H Lok, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
European Urology|October 30, 2020
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate CancerM Brent McHenry, Charles G Drake, Karim Fizazi
The New England Journal of Medicine|July 5, 2018
Immune Checkpoint Blockade in Advanced Renal-Cell CarcinomaRobert J Motzer, M Brent McHenry, Allen C Chen
Biometrika|October 11, 2012
Empirical Bayes estimation for additive hazards regression modelsDebajyoti Sinha, M Brent McHenry, Stuart R Lipsitz, et al.
American Journal of Physiology. Renal Physiology|June 29, 2007
Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathyYan Tan, Joo-Seob Keum, Bing Wang, et al.
European Urology|November 17, 2019
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214Bernard Escudier, Robert J Motzer, Nizar M Tannir, et al.
Breast Cancer Research and Treatment|May 8, 2013
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancerHope S Rugo, Mario Campone, Dino Amadori, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2008
Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetesAyad A Jaffa, William R Usinger, M Brent McHenry, et al.
Metabolism: Clinical and Experimental|September 18, 2004
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclassesRichard L Klein, M Brent McHenry, Kerry H Lok, et al.
Japanese Journal of Clinical Oncology|April 19, 2017
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 studyYoshihiko Tomita, Satoshi Fukasawa, Nobuo Shinohara, et al.
Journal of Diabetes and Its Complications|January 12, 2005
Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohortRichard L Klein, M Brent McHenry, Kerry H Lok, et al.
Pageof 3